Search
Garadacimab
go.drugbank.com/drugs/DB15629Approved[L53283] It was developed by CSL Behring for use as a prophylactic agent in patients with hereditary angioedema (HAE), a rare autosomal dominant disorder that results in acute episodes of angioedema. … Garadacimab is a fully human monoclonal antibody targeted against activated factor XII.
Arimoclomol
go.drugbank.com/drugs/DB05025ApprovedArimoclomol is a hydroxylamine derivative [A264414] and a heat-shock protein-70 (HSP70) co-inducer. … [L51384] Arimoclomol was approved by the FDA on September 20, 2024, making it the first treatment for Niemann-Pick disease, type C (NPC).
CPD 923
go.drugbank.com/drugs/DB05856ExperimentalCPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile.
Artemether
go.drugbank.com/drugs/DB06697ApprovedInvestigationalArtemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy.
D-Tryptophan
go.drugbank.com/drugs/DB03225ExperimentalTryptophan is one of the 20 standard amino acids, as well as an essential amino acid in the human diet. It is encoded in the standard genetic code as the codon UGG. … The distinguishing structural characteristic of tryptophan is that it contains an indole functional group. It is an essential amino acid as defined by its growth effects on rats.
N2-[(benzyloxy)carbonyl]-n1-[(3S)-1-cyanopyrrolidin-3-yl]-l-leucinamide
go.drugbank.com/drugs/DB03456ExperimentalThese are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom. It is known to target cathepsin K. … N2-[(benzyloxy)carbonyl]-n1-[(3S)-1-cyanopyrrolidin-3-yl]-l-leucinamide is a solid. This compound belongs to the n-acyl-alpha amino acids and derivatives.
Carbenicillin
go.drugbank.com/drugs/DB00578ApprovedIt is susceptible to gastric juice and penicillinase and may damage platelet function.
Obecabtagene autoleucel
go.drugbank.com/drugs/DB17362ApprovedInvestigationalObecabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy with a fast off-rate binding profile for CD19. … [A265040,A265045] It works by targeting B-cell-specific CD19 surface markers present on malignant B cells.
Categories: Genetically-modified Autologous T Cells, CD19-Directed Genetically Modified Autologous T-cell ImmunotherapiesSynonyms: A CHIMERIC ANTIGEN RECEPTOR (CAR) CONSISTING O, AUTOLOGOUS CD4+ AND CD8+ T CELLS, ENRICHED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) OBTAINED BY APHERESIS TRANSDUCED EX VIVO WITH A NON-REPLICATING, SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODINGMitoxantrone
go.drugbank.com/drugs/DB01204ApprovedInvestigationalAn anthracenedione-derived antineoplastic agent.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic IndexTovorafenib
go.drugbank.com/drugs/DB15266ApprovedInvestigational[A263597] It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements. … Tovorafenib is a selective type II RAF kinase inhibitor with anti-tumour activity.